Corporate Factsheet

Name Dimerix Limited (ASX:DXB)
Business Description Dimerix (ASX: DXB) is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology. Incorporated in 2004, Dimerix develops and commercialises pharmaceutical products for global markets using innovative receptor technology to identify and then develop drugs in areas with an unmet need. Each product is designed to be preferred by patients over current therapies.
Dimerix has used its proprietary Receptor-HIT technology to identify a new treatment (DMX-200) that may transform the lives of patients with Kidney Disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development. Read more about Dimerix
Shares on Issue 158,799,437 ordinary shares
Controlled Entities Dimerix Biosciences Pty Ltd (100% owned by Dimerix Limited)
CEO Nina Webster
Board of Directors James Williams – Non-Executive Chairman
Nina Webster – CEO & Managing Director
Hugh Alsop – Non-Executive Director
Sonia Poli - Non-Executive Director
David Franklyn - Non-Executive Director

Human Capital Committee and Audit & Risk Committee functions assumed by the Board
Company Secretary Hamish George
Registered Office 425 Smith Street, Fitzroy, Victoria 3065, AUSTRALIA
Phone +61 1300 813 321
Email investor@dimerix.com
Web https://dimerix.com/Opens in new window
Share Registry Automic Pty Ltd.
Suite 1a, Level 1
7 Ventnor Avenue
West Perth, Western Australia 6005
Tel: +61 8 9324 2099
Fax: +61 8 9321 2337
Email: hello@automic.com.au
Web: https://automic.com.auOpens in new window
Auditor Stantons International
Level 2, 1 Walker Avenue
West Perth, Western Australia 6005

Join the Dimerix mailing list to receive the latest company news.

Join now